C
Chrisanthi A. Karanikas
Researcher at Eli Lilly and Company
Publications - 12
Citations - 583
Chrisanthi A. Karanikas is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Type 2 diabetes & Dulaglutide. The author has an hindex of 7, co-authored 9 publications receiving 189 citations.
Papers
More filters
Journal ArticleDOI
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
Julio Rosenstock,Carol Wysham,Juan P. Frias,Shizuka Kaneko,Clare J. Lee,Laura Fernández Landó,Huzhang Mao,Xuewei Cui,Chrisanthi A. Karanikas,Vivian T. Thieu +9 more
TL;DR: Tirzepatide as discussed by the authors showed robust improvements in glycaemic control and bodyweight, without increased risk of hypoglycaemia, in a 40-week, double-blind, randomised, placebo-controlled, phase 3 trial at 52 medical research centres and hospitals in India, Japan, Mexico, and USA.
Journal ArticleDOI
Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes
Mark L. Hartman,Arun J. Sanyal,Rohit Loomba,Jonathan M. Wilson,Amir Nikooienejad,Ross Bray,Chrisanthi A. Karanikas,Kevin L. Duffin,Deborah A. Robins,Axel Haupt +9 more
TL;DR: Higher tirzepatide doses significantly decreased NASH-related biomarkers and increased adiponectin in patients with type 2 diabetes mellitus (T2DM).
Journal ArticleDOI
Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme.
Kenneth Cusi,Naveed Sattar,Luis-Emilio Garcia-Perez,Imre Pavo,Maria Yu,Kenneth E. Robertson,Chrisanthi A. Karanikas,Axel Haupt +7 more
TL;DR: To evaluate the effects of dulaglutide vs placebo on liver and glycaemic/metabolic measurements in a population with Type 2 diabetes and in a subgroup with non‐alcoholic fatty liver/non-alcoholic steatohepatitis.
Journal ArticleDOI
Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States.
Kristina S. Boye,Matthew C. Riddle,Hertzel C. Gerstein,Reema Mody,Luis-Emilio Garcia-Perez,Chrisanthi A. Karanikas,Maureen J. Lage,Jeffrey S. Riesmeyer,Mark Lakshmanan +8 more
TL;DR: To examine the generalizability of results from glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) cardiovascular outcome trials (CVOTs) in the US type 2 diabetes population, a large number of trials were conducted in the T2D population.
Journal ArticleDOI
Low incidence of anti-drug antibodies in patients with type 2 diabetes treated with once-weekly glucagon-like peptide-1 receptor agonist dulaglutide.
Zvonko Milicevic,Greg Anglin,Kristine D. Harper,Robert J. Konrad,Zachary Skrivanek,Wolfgang Glaesner,Chrisanthi A. Karanikas,Kenneth F. Mace +7 more
TL;DR: The incidence of treatment‐emergent dulaglutide ADAs, hypersensitivity AEs, injection site reactions (ISRs), and glycaemic control in ADA‐positive patients in nine phase II and phase III trials was assessed.